Table 2 Statistical comparison of combined expression of AR-V3, AR-V7 and AR-V9 in different sample types using two-tailed, unpaired Mann-Whitney U test

From: Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases

 

Prostatectomy

Lymph node metastases

Prostatectomy

-

 

Lymph node metastases

0.1765

-

CRPC metastases

0.0006***

0.0282*

  1. CRPC castration-resistant prostate cancer.
  2. *p < 0.05, ***p < 0.001. Statistically significant p-values are shown in bold
Back to article page